Cargando…
BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is characterized by the accumulation of Langerin (CD207)-expressing histiocytes. Mutational activation of mitogen-activated protein kinase pathway genes, in particular BRAF, drives most cases. To test whether activated BRAF is sufficient for the development of LCH...
Autores principales: | Nelson, David S., Marano, Ryan L., Joo, Yechaan, Tian, Sara Y., Patel, Bhumi, Kaplan, Daniel H., Shlomchik, Mark J., Stevenson, Kristen, Bronson, Roderick T., Rollins, Barrett J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748438/ https://www.ncbi.nlm.nih.gov/pubmed/31527903 http://dx.doi.org/10.1371/journal.pone.0222400 |
Ejemplares similares
-
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
por: Bates, Sara V., et al.
Publicado: (2013) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020) -
BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016) -
Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)